Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13605 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2024. Verfasst von Rossella Scardaci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Italy. Hauptthemen laut MEDLINE: ras Proteins, raf Kinases, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 206 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Giovanni Armenise-Harvard Foundation, European Research Council (ERC), Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Mutations in the RAS–RAF–MEK–ERK pathway are frequent alterations in cancer and RASopathies, and while RAS oncogene activation alone affects 19% of all patients and accounts for approximately 3.4 million new cases every year, less frequent alterations in the cascade's downstream effectors are also involved in cancer etiology. RAS proteins initiate the signaling cascade by promoting the dimerization of RAF kinases, which can act as oncoproteins as well: BRAF V600E is the most common oncogenic driver, mutated in the 8% of all malignancies. Research in this field led to the development of drugs that target the BRAFV600‐like mutations (Class I), which are now utilized in clinics, but cause paradoxical activation of the pathway and resistance development. Furthermore, they are ineffective against non‐BRAFV600E malignancies that dimerize and could be either RTK/RAS independent or dependent (Class II and III, respectively), which are still lacking an effective treatment. This review discusses the recent advances in anti‐RAF therapies, including paradox breakers, dimer‐inhibitors, immunotherapies, and other novel approaches, critically evaluating their efficacy in overcoming the therapeutic limitations, and their putative role in blocking the RAS pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Italy.
- Department of Oncology, University of Torino, San Luigi Hospital, Orbassano, Italy.
- Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Spain.
ORCID-Profile: Chiara Ambrogio
Förderung
- Giovanni Armenise-Harvard Foundation
- European Research Council (ERC)
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Scardaci, R., Berlinska, E., Scaparone, P., Vietti Michelina, S., Garbo, E., Novello, S., Santamaria, D., & Ambrogio, C. (2024). Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node. Molecular Oncology. https://doi.org/10.1002/1878-0261.13605
Vancouver
Scardaci R, Berlinska E, Scaparone P, Vietti Michelina S, Garbo E, Novello S, et al. Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node. Molecular Oncology. 2024. doi:10.1002/1878-0261.13605
BibTeX
@article{Scardaci2024,
author = {Scardaci, Rossella and Berlinska, Ewa and Scaparone, Pietro and Vietti Michelina, Sandra and Garbo, Edoardo and Novello, Silvia and Santamaria, David and Ambrogio, Chiara},
title = {Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13605}
}
EUVIMED